Advice for Community Oncologists Treating Renal Cell Carcinoma

Video

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
      Treatment of Earlier-Stage Disease May Strengthen NMIBC-Related Survival
      Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
      Sasanlimab Combo Improves EFS “Across the Board” in BCG-Naive NMIBC
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
      Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
      Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
      Outlining Risk Factor Identification and Mitigation in Bladder Cancer
      How a Radiation Oncologist Answers Patient Questions with Research
      How a Radiation Oncologist Answers Patient Questions with Research
      There Is Excitement and Advances in SBRT Treatment For RCC
      There Is Excitement and Advances in SBRT Treatment For RCC
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      Related Content
      The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

      FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

      Roman Fabbricatore
      June 18th 2025
      Article

      The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

      A Sneak Peek at 2025 ASCO From the GU Perspective

      A Sneak Peek at 2025 ASCO From the GU Perspective

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      May 15th 2025
      Podcast

      Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

      The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

      CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

      Roman Fabbricatore
      June 3rd 2025
      Article

      The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

      Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

      Finding Ways to Break the Mold in GU Oncology

      Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
      April 8th 2024
      Podcast

      Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

      Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

      ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

      Roman Fabbricatore
      May 21st 2025
      Article

      Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

      Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

      FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

      Tim Cortese;Ariana Pelosci
      May 14th 2025
      Article

      Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.